TrialDiabetes care2020

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.

Mark L Hartman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.